Changes in Some Immunological and Biochemical Parameters in Patients with Chronic Hepatitis C with Increased Total Cardiovascular Risk and their Medical Correction

Near 150 million people around the world suffer from chronic hepatitis C and 350 ? 500 thousand die annually. Despite the large amount of studies devoted to the study of HCV-infection, the mechanisms of progression of chronic hepatitis C in patients with concomitant pathology are not quite determined today. The objective of this study was to examine the clinical-laboratory efficiency of treatment of chronic hepatitis C patients with increased total cardiovascular risk introducing medicine containing ribonucleic acid into the therapeutic regimen. The obtained results showed that the comprehensive application of antiviral therapy and ribonucleic acid-based medicine was accompanied by normalization of cytolytic syndrome, especially in patients with minimal or moderately manifested activity of hepatitis. In addition, a pronounced positive effect on rebalancing of the levels of biochemical parameters and cytokines was determined. For patients’ treatment it is appropriate to use ribonucleic acid-based medicine at a dose of 1.5 grams per day.